Table 2.
Elwatidy et al. [18] | Farrokhi et al. [19] | Neilipovitz et al. [20] | Sethna et al. [21] | Tsutsumimoto et al. [22] | Wong et al. [23] | |
---|---|---|---|---|---|---|
Eligibility criteria | 1 | 1 | 1 | 1 | 1 | 1 |
Random allocation | 0 | 1 | 1 | 1 | 0 | 1 |
Concealed allocation | 1 | 1 | 1 | 0 | 0 | 1 |
Baseline comparability | 1 | 1 | 1 | 1 | 1 | 1 |
Blind subject | 1 | 1 | 1 | 0 | 0 | 1 |
Blind clinician | 1 | 1 | 1 | 0 | 0 | 1 |
Blind assessor | 1 | 1 | 1 | 0 | 1 | 1 |
Adequate follow-up | 1 | 0 | 1 | 1 | 1 | 1 |
Intention-to treat analysis | 0 | 1 | 1 | 1 | 1 | 0 |
Between-group analysis | 1 | 1 | 1 | 1 | 1 | 1 |
Point estimates and variability | 1 | 1 | 1 | 1 | 1 | 1 |
Total score | 9 | 10 | 11 | 7 | 7 | 10 |